The role of anticholinergic bronchodilators in adult asthma and chronic obstructive pulmonary disease.

Abstract

Our renewed interest in anticholinergic bronchodilator therapy has been sparked by the development of safe yet effective quaternary anticholinergic compounds including ipratropium bromide, oxitropium and atropine methonitrate. These agents offer gradual and sustained bronchodilation to patients with asthma and to patients with COPD. However, their role in the maintenance treatment of these two diseases differs significantly. In asthma, the anticholinergic drugs have useful additive properties when used with adrenergic drugs or theophylline. They may be a particularly useful component of combination regimens in patients with disease of more than mild severity and in older patients. The combination of inhaled adrenergic and anticholinergic drugs is also useful in the acute setting for acute exacerbations of asthma. In chronic obstructive lung disease, the anticholinergic compounds offer greater bronchodilatation than adrenergic drugs for the majority of patients. Thus, the inhaled anticholinergic drugs may be considered as useful initial choices in the chronic maintenance therapy of COPD.

• Authors: K R Chapman
• Journal: Lung (Lung) Vol. 168 Suppl Pg. 295-303 ( 1990) ISSN: 0341-2040 [Print] United States
• PMID: 2143551 (Publication Type: Journal Article, Review)

Chemical References

• Bronchodilator Agents
• Parasympatholytics
• Ipratropium

Topics

• Adult
• Airway Resistance (drug effects)
• Asthma (drug therapy)
• Bronchodilator Agents (therapeutic use)
• Forced Expiratory Volume (drug effects)
• Humans
• Ipratropium (therapeutic use)
• Lung Diseases, Obstructive (drug therapy)
• Parasympatholytics (therapeutic use)